[Clinical results after hemodilution with hydroxyethyl starch in pregnancy].
Plasma volume contraction in pregnancy is diagnosed by an increase of hematocrit above 38%. Hydroxyethylstarch was administered to 30 patients with hemoconcentration alone, to 36 patients with fetal growth weight retardation and to two patients with pre-eclampsia. In the present study the tolerance and effectiveness of middle molecular hydroxyethylstarch as volume replacement was studied. The data presented a significant decrease in the incidence of small for date babies (from 52% to 34%). In addition to these findings, hematocrit, erythrocyte aggregation and plasma viscosity were decreased and cardiac output was increased. By twenty three women we registered a newborn weight below the 10th percentile according to Hohenauer. The impaired rheological properties of blood in this group were associated with a decrease of cardiac output. We conclude that hydroxyethylstarch is a safe (no maternal-fetal transfer and only a small incidence of starch storage (1.4% of patients) in the placenta) and effective colloid substance for plasma volume expansion in pregnancy.
Heilmann
L
L
Abt. für Perinatologie, Klinikum Essen.
D000328:Adult; D003681:Dehydration / Q000188:drug therapy*; D004903:Erythrocyte Aggregation / Q000188:drug therapy*; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy; D006438:Hemodilution; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D013213:Starch
D006895:Hydroxyethyl Starch Derivatives; D013213:Starch
Klinische Ergebnisse nach Hämodilution mit Hydroxyäthylstärke in der Schwangerschaft.